ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

BVXP.GB Bioventix Plc

4,625.00
0.00 (0.00%)
28 Mar 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
Bioventix Plc AQSE:BVXP.GB Aquis Stock Exchange Ordinary Share GB00B4QVDF07
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4,625.00 4,350.00 4,900.00 4,625.00 4,499.00 4,625.00 70 16:29:58
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Bioventix Plc Trading Update and Notice of Results

22/08/2016 7:00am

UK Regulatory


 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or the "Company") 
 
                     Trading Update and Notice of Results 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for application in 
clinical diagnostics, announces a trading update. 
 
The Board is pleased to report that revenues for the financial year ended 30 
June 2016 are expected to be in excess of GBP5.3M (2015: GBP4.33M). A strong 
performance during the financial year has been supplemented by a positive 
exchange rate effect. Since the cost base of the Company follows the same 
trajectory as in previous years, both revenues and profits before tax are 
expected to be  ahead of market expectations for the year ended 30 June 2016. 
 
The Board is encouraged by the recent development activities of our partner, 
Siemens Healthcare Diagnostics. A Bioventix-created antibody is being used in a 
Siemens troponin product that is under development, as mentioned in a 
scientific presentation at the August 2016 American Association of Clinical 
Chemistry. Troponin remains an important product for Bioventix's future 
performance, as we expect to commence significant sales during the financial 
year ending 30 June 2018, which will offset revenues from other products which 
are expected to reduce during this period. 
 
Notice of Results 
 
The audited accounts for the year ended 30 June 2016 are due to be released on 
Monday 17 October 2016. 
 
The information communicated in this announcement contains inside information 
for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014. 
 
For further information please contact: 
 
Bioventix plc                                     Tel: 01252 728 001 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: 020 7220 0500 
Geoff Nash/Simon Hicks   Corporate Finance 
Stephen Norcross         Corporate Broking 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
 
 
END 
 

(END) Dow Jones Newswires

August 22, 2016 02:00 ET (06:00 GMT)

1 Year Bioventix Chart

1 Year Bioventix Chart

1 Month Bioventix Chart

1 Month Bioventix Chart

Your Recent History

Delayed Upgrade Clock